

Date: 8<sup>th</sup> July 2025.  
Ref: CORP 25/26 - 058

Dear xxx

**Freedom of Information request: Treatment of Melanoma (CORP 25/26 – 058)**

Thank you for your request for information which the Trust received on 19<sup>th</sup> June 2025.

Your Request:

Q1. *How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):*

- *Cobimetinib*
- *Dabrafenib*
- *Dabrafenib + Trametinib*
- *Dacarbazine*
- *Denosumab*
- *Encorafenib + Binimetinib*
- *Ipilimumab monotherapy*
- *Ipilimumab + Nivolumab*
- *Nivolumab monotherapy*
- *Nivolumab + Relatlimab*
- *Pembrolizumab*
- *Trametinib*
- *Vemurafenib*
- *Vemurafenib + Cobimetinib*
- *Other active systemic anti-cancer therapy*
- *Palliative care only*

Q2. *In the last 3 months, how many patients have been initiated\* on the following agents for treatment for melanoma?*

- *Ipilimumab (monotherapy)*
- *Nivolumab (monotherapy)*
- *Nivolumab AND Ipilimumab (combination)*
- *Nivolumab AND Relatlimab*
- *Pembrolizumab*
- *Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)*
- *Other active systemic anti-cancer therapy*

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.

*\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Q3. Does your trust participate in any clinical trials for Melanoma? If so, please provide the name of each trial, and the number of patients taking part.

Please find the Trust's response below:

**Q1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):**

- **Cobimetinib - 0**
- **Dabrafenib - 0**
- **Dabrafenib + Trametinib - 11**
- **Dacarbazine - 0**
- **Denosumab - 6**
- **Encorafenib + Binimetinib - 0**
- **Ipilimumab monotherapy - <6\***
- **Ipilimumab + Nivolumab - 11**
- **Nivolumab monotherapy - 40**
- **Nivolumab + Relatlimab - 0**
- **Pembrolizumab - 82**
- **Trametinib - 0**
- **Vemurafenib - 0**
- **Vemurafenib + Cobimetinib - 0**
- **Other active systemic anti-cancer therapy - <6\***
- **Palliative care only - 20**


Data shows number of unique patients treated with the above, as such some of these patients may have received more than one of these drugs/treatments.

\* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

**Q2. In the last 3 months, how many patients have been initiated\* on the following agents for treatment for melanoma?**

- **Ipilimumab (monotherapy) - 0**
- **Nivolumab (monotherapy) - <6\***
- **Nivolumab AND Ipilimumab (combination) - <6\***
- **Nivolumab AND Relatlimab – 0**

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.



- **Pembrolizumab - 23**
- **Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib) - <6\***
- **Other active systemic anti-cancer therapy - 0**

**\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**

Data shows number of unique patients treated with the above, as such some of these patients may have received more than one of these drugs/treatments.


\* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

**Q3. Does your trust participate in any clinical trials for Melanoma? If so, please provide the name of each trial, and the number of patients taking part.**

Short Title	Participants Recruited
BI-1607 - AN OPEN-LABEL, MULTICENTRE PHASE 1B/2A CLINICAL TRIAL OF BI-1607, AN FC-ENGINEERED MONOCLONAL ANTIBODY TO FC $\gamma$ RIIB (CD32B), IN COMBINATION WITH IPILIMUMAB AND PEMBROLIZUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA	0
SCC-AFTER - Adjuvant radiotherapy in patients with high-risk primary cutaneous Squamous Cell Carcinoma AFTER surgery (SCC-AFTER): an open label, multicentre, two-arm phase III randomised trial	0
MITRE - Microbiome Immunotherapy Toxicity and Response Evaluation	25
Scancell (The SCOPE Study) - A Phase 2, Multicenter, Open-Label Study of SCIB1 in Patients with Advanced Unresectable Melanoma Receiving Pembrolizumab	10
DyNAMIC - Circulating tumour DNA guided Adaptive BRAF and MEK Inhibitor therapy	0

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.



You should forward your complaint to:

Mr Ian Bevan via [FOI.VUNHST@wales.nhs.uk](mailto:FOI.VUNHST@wales.nhs.uk)  
Head of Information Governance  
Velindre University NHS Trust  
2, Charnwood Court  
Heol Billingsley  
Parc Nantgarw  
Cardiff  
CF15 7QZ

Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:

Information Commissioner's Office - Wales  
2nd Floor  
Churchill House  
Churchill Way  
Cardiff  
CF10 2HH  
Telephone: 0330 414 6421  
email: [wales@ico.org.uk](mailto:wales@ico.org.uk)

Yours sincerely

**Non Gwilym**  
**Interim Director of Corporate Governance**  
Velindre University NHS Trust  
2 Charnwood Court  
Heol Billingsley  
Parc Nantgarw  
Cardiff  
CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.

